Form 4: Theravance Biopharma Executive Aine Miller Reports Acquisition of 37,500 Ordinary Shares
SEC Form 4 Filing
Aine Miller, SVP at Theravance Biopharma, reports acquiring 37,500 ordinary shares on April 2, 2024.
Summary
- A Form 4 filing reveals that Aine Miller, SVP, DEV & Head of IRE Office at Theravance Biopharma, acquired 37,500 ordinary shares on April 2, 2024.
- The shares were acquired directly.
- Following the transaction, Miller beneficially owns 171,034 ordinary shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing reporting a transaction. The acquisition of shares by an executive could be seen as a slightly positive signal, but it's not definitive.
Positives
- The acquisition of shares by a company executive could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's stock.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/02/2024 | Date of transaction: Aine Miller acquired 37,500 ordinary shares. |
| 04/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.